RepliCel is a regenerative medicine company focused on developing autologous that address diseases caused by a deficit of healthy cells required for normal healing and function. The company’s RCT-01, RCS-01, and are designed to treat chronic tendinosis, UV-damaged or aged skin, and pattern baldness. has an exclusive license for RCH-01 in certain Asian countries including Japan, China and South Korea. All product candidates are based on RepliCel’s innovative technology utilizing cell populations isolated from a patient’s own healthy hair follicles. The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications.  The Company’s product pipeline is comprised of multiple anticipated to launch through 2015, in addition to ’s own clinical trial of RCH-01 and the device in late prototype development. Please visit www.replicel.com for additional information.

Tags

 
 
 
 

Enjoy this site? Please spread the word :)

RSS
EMAIL
SHARE